Showing 261-270 of 325 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Development and Preclinical Assessment of a Biovascular Pancreas | Humacyte | Kaleb Naegeli | Cures | 01-April-2023 to 28-February-2027 | $863,333.00 |
| Goals of Care Among Caregivers of Youth with T1D Using The 3-Act Model | Hugo W. Moser Research Institute at Kennedy Krieger | Karen Dimentstein | Transportfolio | 01-September-2024 to 31-August-2026 | $130,000.00 |
| Advanced Oxygen Generator for Oxygenated Cell Capsules | Giner, Inc. | Linda Tempelman | Cures | 01-June-2021 to 30-September-2026 | $448,173.29 |
| Hydrogels for Islet Engraftment in the Porcine Subcutaneous Space | Georgia Tech Research Corporation | Andres Garcia | Cures | 01-November-2025 to 31-October-2028 | $771,544.57 |
| Synthetic Hydrogels for Islet Vascularization and Engraftment | Georgia Tech Research Corporation | Andres Garcia | Cures | 01-July-2022 to 30-June-2026 | $563,235.05 |
| A Novel Magnetorheological Insulin Pump | Georgia Southern University Research and Service Foundation, Inc | Sevki Cesmeci | Improving Lives | 01-June-2023 to 31-May-2026 | $199,516.50 |
| GNTI-122 for the treatment of recently diagnosed type 1 diabetes | GentiBio | Mark Bach | Cures | 01-December-2025 to 30-November-2027 | $4,000,000.00 |
| Using genetics to better diagnose and treat adult-onset T1D in multi-ethnic US population | Geisinger Clinic | David Carey | Cures | 01-November-2022 to 30-September-2026 | $1,469,640.10 |
| Development of a new nanotechnology for immune-tolerizing therapy against T1D | EVOQ Therapeutics, Inc. | Vishalakshi Krishnan | Cures | 01-September-2022 to 28-February-2026 | $1,110,000.00 |
| Evaluating the Effectiveness and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 1 Diabetes | Emory University | Hui Shao | Improving Lives | 01-July-2025 to 30-June-2027 | $599,998.91 |